Last updated date
ABOUT THIS STUDY
The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of
patients during dialysis.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Renal Failure
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-85 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- chronic renal failure on hemodialysis
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- significant comorbidities that would prevent a patient from completing the trial
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Chronic Renal FailureUse Of Fragmin In Hemodialysis
NCT01879618
- Edmonton, Alberta
- Edmonton, Alberta
- Edmonton, Alberta
- Saint John, New Brunswick
- St. John's, Newfoundland and Labrador
- St. John's, Newfoundland and Labrador
- St. John's, Newfoundland and Labrador
- Halifax, Nova Scotia
- Brampton, Ontario
- London, Ontario
- London, Ontario
- Orangeville, Ontario
- Greenfield Park, Quebec
- Greenfield Park, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Saint-Lambert, Quebec
- Quebec,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Use Of Fragmin In Hemodialysis | |||
| Official Title ICMJE | A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study | |||
| Brief Summary | The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Chronic Renal Failure | |||
| Intervention ICMJE | Drug: Fragmin
variable dosing regimen | |||
| Study Arms ICMJE | Experimental: Fragmin
Fragmin given according to the flexible dosing regimen outlined in the protocol Intervention: Drug: Fragmin | |||
| Publications * | Soroka S, Agharazii M, Donnelly S, Roy L, Muirhead N, Cournoyer S, MacKinnon M, Pannu N, Barrett B, Madore F, Tennankore K, Wilson JA, Hilton F, Sherman N, Wolter K, Orazem J, Feugère G. An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study). Can J Kidney Health Dis. 2018 Nov 4;5:2054358118809104. doi: 10.1177/2054358118809104. eCollection 2018. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 152 | |||
| Original Estimated Enrollment ICMJE | 150 | |||
| Actual Study Completion Date ICMJE | March 2016 | |||
| Actual Primary Completion Date | March 2016 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 85 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Canada | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT01879618 | |||
| Other Study ID Numbers ICMJE | A6301091 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | January 2017 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||